The Video Journal of Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review!
For more news visit www.vjhemonc.com
The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately 30% of patients with acute myeloid leukemia (AML) and... The post COSTEM: maintenance therapies for FLT3+ AML appeared first on VJHemOnc.
8 min 48 sec
Over the past few years, the therapeutic landscape for acute lymphoblastic leukemia (ALL) has dramatically evolved, with the development of... The post COSTEM: the role of alloHSCT in ALL appeared first on VJHemOnc.
12 min 39 sec
Over the last two decades the outcomes of patients with amyloidosis have substantially improved with timely diagnosis, the use of... The post SOHO 2021: amyloidosis treatment updates appeared first on VJHemOnc.
6 min 33 sec
Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia,... The post IACH 2021: CAR-T in clinical practice appeared first on VJHemOnc.
17 min 53 sec
The treatment of chronic myeloid leukemia (CML) has substantially evolved since the FDA approval of the tyrosine kinase inhibitor imatinib... The post Unmet needs and recent updates in CML appeared first on VJHemOnc.
4 min 13 sec
Continuous therapy has been a key aspect of the standard of care approaches for the treatment of multiple myeloma for... The post IMW 2021: treatment-free intervals in multiple myeloma appeared first on VJHemOnc.
The management of chronic lymphocytic leukemia (CLL) has evolved drastically over the last few years, with the introduction of novel... The post Highlights from iwCLL 2021 appeared first on VJHemOnc.
18 min 54 sec
Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence... The post IMW 2021: MRD in myeloma appeared first on VJHemOnc.
21 min 14 sec
Autologous stem cell transplantation (ASCT) has been the standard of care patients with multiple myeloma for the past three decades;... The post CAR-T vs bispecifics: replacing ASCT in myeloma appeared first on VJHemOnc.
10 min 32 sec
Antibody therapies are rapidly transforming the treatment landscape of non-Hodgkin lymphoma (NHL). Since the development of rituximab as an anti-CD20... The post EHA 2021: antibody therapies for NHL appeared first on VJHemOnc.
17 min 11 sec